Open AccessLong-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
Author(s) -
Miriam López-Gómez,
Maria J. Merino,
Enrique Casado
Publication year - 2012
Publication title -
clinical medicine insights oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 26
ISSN - 1179-5549
DOI - 10.4137/cmo.s5055
Subject(s) - panitumumab , colorectal cancer , medicine , oncology , monoclonal antibody , chemotherapy , disease , cancer , cetuximab , antibody , immunology
Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. More than 30% patients present with metastases at diagnoses and will require systemic chemotherapy. In recent years many anti-EGFR targets have been developed. Among them, panitumumab, a fully human IgG2 monoclonal antibody has shown important benefits in the treatment of this disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom